title: Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.
abstract: BACKGROUND
  In the advanced stages of the acquired immunodeficiency syndrome (AIDS), cytomegalovirus (CMV) disease, particularly vision-damaging retinitis due to CMV is common. We evaluated prophylactic treatment with orally administered ganciclovir as a way to prevent CMV disease.
  
  
  METHODS
  We conducted a prospective, randomized, double-blind, placebo-controlled study of CMV infected persons with AIDS with either CD4+ lymphocyte counts of < or = 50 per cubic millimeter or counts of < or = 100 per cubic millimeter in those with a history of an AIDS defining opportunistic infection. Patients were randomly assigned, in a 2:1 ratio, to receive either oral ganciclovir (1000 mg three times daily) or placebo.
  
  
  RESULTS
  The study was stopped after a median 367 days of follow-up. In an intention-to-treat analysis, the twelve month cumulative rates of confirmed CMV disease were 26 percent in the placebo group (n = 239) and 14 percent in the ganciclovir group (n = 486), representing an overall reduction in risk of 49 percent in the ganciclovir group (P < 0.001). The incidence of CMV retinitis after 12 months was 24 percent in the placebo group and 12 percent in the ganciclovir group (P < 0.0001). The prevalence of CMV-positive urine cultures at base line was 42 percent; after two months it was 43 percent in the placebo group and 10 percent in the ganciclovir group (P < 0.0001). The one year mortality rate was 26 percent in the placebo group and 21 percent in the ganciclovir group (P = 0.14). Therapy with granulocyte colony stimulating factor was more frequent in the ganciclovir group (24 percent) than in the placebo group (9 percent).
  
  
  CONCLUSIONS
  In persons with advanced AIDS, phophylactic oral ganciclovir significantly reduces the risk of CMV disease.
authors.affiliation: University of California, San Diego, La Jolla, 92093-0672, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Spector
authors.forename: G F
authors.initials: GF
authors.lastname: McKinley
authors.forename: J P
authors.initials: JP
authors.lastname: Lalezari
authors.forename: T
authors.initials: T
authors.lastname: Samo
authors.forename: R
authors.initials: R
authors.lastname: Andruczk
authors.forename: S
authors.initials: S
authors.lastname: Follansbee
authors.forename: P D
authors.initials: PD
authors.lastname: Sparti
authors.forename: D V
authors.initials: DV
authors.lastname: Havlir
authors.forename: G
authors.initials: G
authors.lastname: Simpson
authors.forename: W
authors.initials: W
authors.lastname: Buhles
authors.forename: R
authors.initials: R
authors.lastname: Wong
authors.forename: M
authors.initials: M
authors.lastname: Stempien
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000401:mortality; D000284:Administration, Oral; D000328:Adult; D018791:CD4 Lymphocyte Count; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D015774:Ganciclovir